Last reviewed · How we verify
ISIS 14803, peginterferon alfa, ribavirin
ISIS 14803, peginterferon alfa, ribavirin is a Small molecule drug developed by Ionis Pharmaceuticals, Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | ISIS 14803, peginterferon alfa, ribavirin |
|---|---|
| Sponsor | Ionis Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ISIS 14803, peginterferon alfa, ribavirin CI brief — competitive landscape report
- ISIS 14803, peginterferon alfa, ribavirin updates RSS · CI watch RSS
- Ionis Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about ISIS 14803, peginterferon alfa, ribavirin
What is ISIS 14803, peginterferon alfa, ribavirin?
ISIS 14803, peginterferon alfa, ribavirin is a Small molecule drug developed by Ionis Pharmaceuticals, Inc..
Who makes ISIS 14803, peginterferon alfa, ribavirin?
ISIS 14803, peginterferon alfa, ribavirin is developed by Ionis Pharmaceuticals, Inc. (see full Ionis Pharmaceuticals, Inc. pipeline at /company/ionis-pharmaceuticals-inc).
What development phase is ISIS 14803, peginterferon alfa, ribavirin in?
ISIS 14803, peginterferon alfa, ribavirin is in Phase 1.